Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events

• Published in: Blood cancer journal (New York) 2023-08, Vol.13 (1), p.122-122, Article 122
• Main Authors: Abdelmagid, Maymona G., Al-Kali, Aref, Litzow, Mark R., Begna, Kebede H., Hogan, William J., Patnaik, Mirinal S., Hashmi, Shahrukh K., Elliott, Michelle A., Alkhateeb, Hassan, Karrar, Omer S., Fleti, Farah, Elnayir, Mohammed H., Rivera, Candido E., Murthy, Hemant S., Foran, James M., Kharfan-Dabaja, Mohamed A., Badar, Talha, Viswanatha, David S., Reichard, Kaaren K., Gangat, Naseema, Tefferi, Ayalew
• Format: Article
• Language: English
• Subjects: 631/67/1990/2331; 692/699/1541/1990/2331; Biomedical and Life Sciences; Biomedicine; Cancer Research; Hematology; Leukemia; Oncology; Remission (Medicine); Transplants & implants
• ISSN: 2044-5385; 2044-5385
• DOI: 10.1038/s41408-023-00891-x

We surveyed the performance of ponatinib, as salvage therapy, in a real-world setting of chronic phase chronic myeloid leukemia (CML-CP). Among 55 consecutive patients (median age 49 years) with relapsed/refractory CML-CP, 35 (64%) had failed ≥3 tyrosine kinase inhibitors (TKIs), 35 (64%) were pre-treated with nilotinib, and 14 (28%) harbored ABL1 T315I. At start of ponatinib (median dose 30 mg/day), 40 patients were already in complete hematologic (CHR), 4 in complete cytogenetic (CCyR), 3 in major molecular (MMR) remission, while 8 had not achieved CHR (NR). Ponatinib improved the depth of response in 13 (33%), 3 (75%), 2 (66%), and 4 (50%) patients with CHR, CCyR, MMR, and NR, respectively ( p  = 0.02). At a median follow-up of 42 months, 13 (23%) deaths, 5 (9%) blast transformations, and 25 (45%) allogeneic transplants were recorded. Five/10-year post-ponatinib survival was 77%/58% with no significant difference when patients were stratified by allogeneic transplant ( p  = 0.94), ponatinib-induced deeper response ( p  = 0.28), or a post-ponatinib ≥CCyR vs CHR remission state ( p  = 0.25). ABL1 T315I was detrimental to survival ( p  = 0.04) but did not appear to affect response. Prior exposure to nilotinib was associated with higher risk of arterial occlusive events (AOEs; 11% vs 0%; age-adjusted p  = 0.04). Ponatinib starting/maintenance dose (45 vs 15 mg/day) did not influence either treatment response or AOEs. Our observations support the use of a lower starting/maintenance dose for ponatinib in relapsed/refractory CML-CP but a survival advantage for deeper responses was not apparent and treatment might not overcome the detrimental impact of ABL1 T315I on survival. The association between prior exposure to nilotinib and a higher risk of post-ponatinib AOEs requires further validation.